Volume 15, Number 9—September 2009
Phylogeny and Disease Association of Shiga Toxin–producing Escherichia coli O91
The diversity and relatedness of 100 Shiga toxin–producing Escherichia coli O91 isolates from different patients were examined by multilocus sequence typing. We identified 10 specific sequence types (ST) and 4 distinct clonal groups. ST442 was significantly associated with hemolytic uremic syndrome.
Shiga toxin–producing Escherichia coli (STEC) infections are public health concerns because of the severe illnesses they cause, such as hemorrhagic colitis and hemolytic uremic syndrome (HUS) (1). STEC constitute a heterogeneous group of bacteria abundant in the reservoir and in the environment (2). Transmission routes for human STEC infection are numerous and include contact with animal excreta, person-to-person transmission, and inadvertent ingestion of contaminated food and water. Many STEC serotypes have been recovered from humans (3,4). Among them, STEC O91 is the most common serogroup isolated from adult patients in Germany (5,6). The strains within this serogroup appear to be transmitted predominantly by food, because 1) food vehicles have been identified as the only risk factors for adults with sporadic STEC O91 infection in Germany (6); 2) O91 is the second most frequently isolated STEC serogroup in routine food samples (5); and 3) O91 is the only major STEC serogroup with no association between incidence of human infection and cattle density (7).
Whereas most human disease STEC serogroups possess, in addition to Shiga toxin, the eae gene encoding the adhesin intimin (3,4,8), STEC O91 consistently lack this virulence determinant (8,9). Despite frequent isolation of STEC O91 from humans, the clonal relatedness of the serotypes of this serogoup is poorly understood. Therefore, we investigated 100 human STEC O91 isolates to determine the clonal structure of STEC O91 and its association with disease.
A total of 100 STEC O91 isolates were obtained from 1997 through 2007 from patients with HUS (n = 4), bloody diarrhea (n = 8), watery diarrhea without visible blood (n = 79), abdominal cramps without diarrhea (n = 1), or from asymptomatic carriers (n = 8); samples were from Germany (n = 96), Austria (n = 2; Austrian Reference Library, Innsbruck, Austria), Finland (n = 1; The National Public Health Institute, Helsinki, Finland), and Canada (n = 1; Public Health Agency of Canada, Guelph, Ontario, Canada). The 96 German O91 strains were recovered at the Institute of Hygiene, University of Münster, Münster, and the Robert Koch Institute, Wernigerode, Germany. The strains included all human isolates of this serogroup that were recovered during the study period in Germany and for which complete clinical information was available. The strains correspond to all O91 serotypes associated with human diseases from sporadic cases in Germany in that interval. Thirty-five strains have been described previously (4,8,10).
The age of patients from whom the STEC O91strains originated ranged from 4 months to 89 years (median 28 years, interquartile range 12–38 years). The most severe symptom was recorded for each patient. Diarrhea was defined as ≥3 semisolid or liquid stools per day. Bloody diarrhea was defined as diarrheal stools containing blood visible to the naked eye. HUS was defined as a case of microangiopathic hemolytic anemia (hematocrit <30% with peripheral evidence of intravascular hemolysis), thrombocytopenia (platelet count <150,000/mm3), and renal insufficiency (serum creatinine concentration greater than the upper limit of normal for age) (11). Asymptomatic carriers were apparently healthy persons without diarrhea; their stools were submitted as noted above.
Strains were isolated using Shiga toxin–encoding genes as diagnostic targets (12) and then serotyped phenotypically (13). All strains were verified as O91 by using PCR targeting wzyO91, a component of the rfb gene cluster that synthesizes the O91 antigen (14). Multilocus sequence typing (MLST) and phylogenetic analysis were performed as described (4). All allelic sequences were deposited in the E. coli MLST database (http://mlst.ucc.ie/mlst/dbs/Ecoli). The minimum spanning tree was generated from all 100 O91 sequence types (STs) and compared with the HUS-associated enterohemorrhagic E. coli (HUSEC) collection (4) to display the distribution of the STs compared with all known STs associated with HUS.
We tabulated disease severity according to STs. To study the relationship between ST442 and disease severity, patients were categorized into those with HUS, those with bloody diarrhea, and, serving as reference group, those with nonbloody diarrhea or those that asymptomatically excreted these organisms. Univariate associations were computed by using exact logistic regression. p values <0.05 were considered statistically significant. STATA release 10.0 (StataCorp LP, College Station, TX, USA) was used for statistical analysis.
The 100 STEC O91 strains resulted in 10 different STs. Of these, STs 33 and 442 were most common (63 and 20 isolates, respectively). Six additional STs (690, 1048, 1051, 1052, 1053, 1054) were single-locus variants of ST33, indicating their close relationship. The 2 remaining STs (641 and 1020) were not closely related to any other ST of the serogroup O91 strains. Detailed analysis of the 7 housekeeping genes used for MLST demonstrated the fumC gene sequence alone could differentiate 5 STs of the O91 strains. The comparison of all O91 STs with all STEC STs and serotypes associated with HUS (HUSEC collection) is displayed in the Figure.
H antigens associated with O91 were H8 (n = 1), H10 (n = 2), H14 (n = 52), H21 (n = 20), Hnt (H-antigen nontypeable) (n = 10), and H– (H-antigen nonmotile) (n = 15). In serotype O91:H8, O91:H10, and O91:H21 strains, the STs were serotype-specific. However, ST33 and its single-locus variants represented all strains of serotypes O91:H14, O91: H–, and O91:Hnt.
A single sequence type, ST442, accounting for 20% of all strains, was found among each of the four O91 isolates from patients with HUS (Table 1), a highly significant association (odds ratio [OR] 27.8, 95% confidence interval [CI] 3.3–∞, p<0.01; Table 2). ST442 strains were also more frequently isolated from patients with bloody diarrhea than were strains belonging to other STs (3/20 [15.0%] vs. 5/80 [6.3%] respectively), but this difference was not statistically significant (Table 2). The overall association with severe disease, defined as either HUS or bloody diarrhea, was strong (OR 7.8, 95% CI 1.83–36.6, p<0.01). Severe illness was noted for 7 (35.0%) of 20 patients infected by ST442 strains, but only for 5 (6.3%) of 80 patients infected by STEC O91 of other STs (Table 2). Patients with bloody diarrhea were younger (median age 12 years) than patients who had mild or no symptoms (median age 20 years). However, this difference was not observed for the 4 patients with HUS (median age 21 years); in this instance, 2 were adults, 1 was 39 months old, and 1 was unknown.
To gain insight into the clonal structure of STEC O91, we determined the relatedness of 100 strains isolated from patients and correlated the clonal lineage to the clinical outcome of the infection. MLST analysis divided the O91 isolates into 10 different STs, whereas classical serotyping identified only 4 complete serotypes (O- and H-antigen). Moreover, MLST was able to type all 25 nonmotile (H–) or nontypeable (Hnt) O91 strains. The analysis demonstrated that the fumC gene from the 7 genes used for MLST was the most heterogeneous and enabled strain differentiation into 5 different STs, among these ST442. It might therefore be a candidate for first-line single-locus sequence typing.
HUS or bloody diarrhea without HUS was significantly associated with ST442, which was represented by serotype O91:H21 only. However, Pradel et al. also reported a case of HUS associated with an O91:H10 isolate that could be differentiated from O91:H21 by using ribotyping (15). In our study, known virulence determinants such as cytolethal distending toxin V or Shiga toxin 2d activatable by elastase in O91:H21 strains (8,10) might contribute to the higher virulence of O91:H21 (ST442). However, further studies of the mechanisms behind the emergence of ST442 in Germany and additional analysis of global O91 isolates are needed. With the MLST approach described, trends and changes in STEC O91 epidemiology and human infections can be carefully surveyed.
Dr Mellmann is a consultant for hygiene and infectious diseases at the University Hospital Münster. His professional interests include molecular identification and epidemiology of STEC and other bacterial pathogens.
We thank M. Karmali, D. Orth, and A. Siitonen for kindly providing O91 strains from their countries. We are also grateful to P. Tarr for critical reading of the manuscript.
This study was supported by grants from the Federal Ministry of Education and Research Network Zoonoses (grant nos. 01KI07124, 01KI07120, 01KI07127, 1368-763) and from the National Reference Laboratory Network of the Robert Koch Institute.
- Karch H, Tarr PI, Bielaszewska M. Enterohaemorrhagic Escherichia coli in human medicine. Int J Med Microbiol. 2005;295:405–18.
- Caprioli A, Morabito S, Brugere H, Oswald E. Enterohaemorrhagic Escherichia coli: emerging issues on virulence and modes of transmission. Vet Res. 2005;36:289–311.
- Brooks JT, Sowers EG, Wells JG, Greene KD, Griffin PM, Hoekstra RM, Non-O157 Shiga toxin–producing Escherichia coli infections in the United States, 1983–2002. J Infect Dis. 2005;192:1422–9.
- Mellmann A, Bielaszewska M, Köck R, Friedrich AW, Fruth A, Middendorf B, Analysis of collection of hemolytic uremic syndrome–associated enterohemorrhagic Escherichia coli. Emerg Infect Dis. 2008;14:1287–90.
- Werber D, Beutin L, Pichner R, Stark K, Fruth A. Shiga toxin–producing Escherichia coli serogroups in food and patients, Germany. Emerg Infect Dis. 2008;14:1803–6.
- Werber D, Behnke SC, Fruth A, Merle R, Menzler S, Glaser S, Shiga toxin–producing Escherichia coli infection in Germany: different risk factors for different age groups. Am J Epidemiol. 2007;165:425–34.
- Frank C, Kapfhammer S, Werber D, Stark K, Held L. Cattle density and Shiga toxin–producing Escherichia coli infection in Germany: increased risk for most but not all serogroups. Vector Borne Zoonotic Dis. 2008;8:635–43.
- Bielaszewska M, Friedrich AW, Aldick T, Schurk-Bulgrin R, Karch H. Shiga toxin activatable by intestinal mucus in Escherichia coli isolated from humans: predictor for a severe clinical outcome. Clin Infect Dis. 2006;43:1160–7.
- Bettelheim KA. The non-O157 Shiga-toxigenic (verocytotoxigenic) Escherichia coli; under-rated pathogens. Crit Rev Microbiol. 2007;33:67–87.
- Bielaszewska M, Fell M, Greune L, Prager R, Fruth A, Tschäpe H, Characterization of cytolethal distending toxin genes and expression in Shiga toxin–producing Escherichia coli strains of non-O157 serogroups. Infect Immun. 2004;72:1812–6.
- Tarr PI, Gordon CA, Chandler WL. Shiga toxin–producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005;365:1073–86.
- Mellmann A, Bielaszewska M, Zimmerhackl LB, Prager R, Harmsen D, Tschäpe H, Enterohemorrhagic Escherichia coli in human infection: in vivo evolution of a bacterial pathogen. Clin Infect Dis. 2005;41:785–92.
- Prager R, Strutz U, Fruth A, Tschäpe H. Subtyping of pathogenic Escherichia coli strains using flagellar (H)–antigens: serotyping versus fliC polymorphisms. Int J Med Microbiol. 2003;292:477–86.
- Perelle S, Dilasser F, Grout J, Fach P. Identification of the O-antigen biosynthesis genes of Escherichia coli O91 and development of a O91 PCR serotyping test. J Appl Microbiol. 2002;93:758–64.
- Pradel N, Boukhors K, Bertin Y, Forestier C, Martin C, Livrelli V. Heterogeneity of Shiga toxin–producing Escherichia coli strains isolated from hemolytic-uremic syndrome patients, cattle, and food samples in central France. Appl Environ Microbiol. 2001;67:2460–8.
Suggested citation for this article: Mellmann A, Fruth A, Friedrich AW, Wieler LH, Harmsen D, Werber D, et al. Phylogeny and disease association of Shiga toxin–producing Escherichia coli 091. Emerg Infect Dis [serial on the Internet] 2009 Sep [date cited]. Available from http://wwwnc.cdc.gov/eid/article/15/9/09-0161
Comments to the Authors
Comments to the EID Editors
Please contact the EID Editors via our Contact Form.
- Page created: December 07, 2010
- Page last updated: December 07, 2010
- Page last reviewed: December 07, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)